2Powell-Dunford N, Cuda AS, Moore JL,et al. Menstrual sup- pression using oral contraceptives: survey of deployed female aviation personnel [J]. Aviat Space Environ Med, 2009, 80 (11): 971-975.
4Santen RS, Song RX, Masarnura S, et al. Adaptation to estradi- ol deprivation causes up-regulation of growth factor pathways and hypersensitivity to estradiol in breast cancer cells[J]. Adv Exp Med Biol, 2008,603 : 19-34.
5Kahlenbom C, Modugno F, Severs WB. Oral contraceptives and breast cancer[J]. Mayo Clin Proc, 2008,83 (7) : 849-850.
二级参考文献36
1Parsey KS, Pong A. An open-label, muhicenter study to evaluate Yasmin, a low-dose combination oral contraceptive containing drospirenone, a new progestogen. Contraception, 2000, 61:105- 111.
2Muhn P, Fuhrmann U, Fritzemeier KH, et al. Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity. Ann N Y Acad Sci, 1995,761:311-335.
3Runnenbaum B, Rabe T. Gynakologische Endokrinologie. Berlin: Springer, 1994:413.
4Oelkers WH. Drospirenone in combination with estrogens: for contraception and hormone replacement therapy. Climacteric, 2005,8 suppl 3 : 19-27.
5Burke AE, Blumenthal PD. Successful use of oral contraceptives. Semin Repord Med, 2001,19:313-321.
6Borges LE, Andrade RP, Aldrighi JM, et al. Effect of a combination of ethinylestradiol 30 μg and drospirenone 3 mg on tolerance, cycle control, general well-being and fluid-related symptoms in women with premenstrual disorders requesting contraception. Contraception, 2006,74:446-450.
7Brown C, Ling F, Wan J. A new monophasic oral contraceptive containing drospirenone. Effect on premenstrual symptoms. J Reprod Med,2002,47 : 14-22.
8Dell DL. Premenstrual syndrome, premenstrual dysphoric disorder, and premenstrual exacerbation of another disorder. Clin Obstet Gynecol, 2004,47:568-575.
9Oelkers WK. Effects of estrogen and progestogens on the reninaldosterone system and blood pressure. Steroids, 1996,61 : 166- 171.
10Eriksson E, Sundblad C, Lisjo P, et al. Serum levels of androgens are higher in women with premenstrual irritability and dysphoria than in controls. Psychoneuroendocrinology, 1992,17 : 195-204.
4Fraser IS,Critchley HO,Broder M,et al.The FIGO recommendations on terminologies and definitions for normal and abnormal uterine bleeding[J].Semin Reprod Med,2011,29:383-390.
5Munro MG,Critchley HO,Fraser IS.The FIGO classification of causes of abnormal uterine bleeding in the reproductive years[J].Fertil Steril,2011,95:2204-2208.
7Salim S,Won H,Nesbitt-Hawes E,et al.Diagnosis andmanagement of endometrial polyps:a critical review of theliterature[J].J Minim Invasive Gynecol,2011,18:569-581.
8Gardner F J,Konje JC,Bell SC,et al.Prevention of tamoxifen induced endometrial polyps using a levonorgestrel releasing intrauterine system long-term follow-up of a randomised control trial[J].Gynecol Oncol,2009,114:452-456.
9Weiss G,Maseelall P,Schott LL,et al.Adenomyosis a variant,not a disease? Evidence from hysterectomized menopausal women in the Study of Women' s Health Across the Nation (SWAN)[J].Fertil Steril,2009,91:201-206.
10Morelli M,Rocca ML,Venturella R,et al.Improvement in chronic pelvic pain after gonadotropin releasing hormone analogue (GnRH-a) administration in premenopausal women suffering from adenomyosis or endometriosis:a retrospective study[J].Gynecol Endocrinol,2013,29:305-308.
